第四十九期水木清华生命科学讲座系列
李兰娟，1947年出生于中国绍兴。现为浙江大学教授、主任医师、博导，传染病诊治国家重点实验室主任，感染性疾病诊治协同创新中心主任，兼任教育部科技委生物与医学学部主任，中华预防医学会副会长等。
从事传染病临床、科研和教学工作40余年，是我国著名的传染病学家。擅长各类肝炎、感染性疾病、新发突发传染病诊治，尤其对肝衰竭、病毒性肝炎、肝病微生态研究有重大突破性贡献。承担了国家“863”“973”、“十五”攻关、国自然等课题20余项，授权发明专利27项。发表论文400余篇，其中在Nature、Lancet、NEJM等SCI收录杂志发表200余篇。2005年被评为中国工程院院士，获国家科技进步一等奖2项，国家科技进步奖（创新团队）1项，国家科技进步二等奖2项，浙江省科技进步一等奖6项。曾荣获“全国优秀科技工作者”称号，“全国杰出专业技术人才”称号，何梁何利基金科学与技术进步奖和中央电视台2014年度科技创新人物，第十一届光华工程科技奖等。
Topic: Gut microbiota: a new territory of therapeutic targeting for infectious disease
Speaker:
Lanjuan Li, M.D.
Director and Professor
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Hangzhou
Abstract:
In the recent 10 years, many studies have revealed, that a variety of environmental factors can affect the intestinal microbial imbalance, which have a close correlation with many diseases. Infectious diseases are disorders caused by pathogens such as viruses, bacteria, fungi or parasites. According to WHO report in 2012：Each year there were 57 million deaths worldwide, 14.9 million of which die of infectious diseases. And more than 2 billion people have been infected with HBV and 240 million people are chronic infections. In addition, HIV continues to be a major global public health issue. Infectious disease remains a serious threat to the survival of mankind! The widely use of broad-spectrum antibiotics, immunosuppressive drugs, and other new modern treatment technology for these disease have a profound impact on the human microbiota. Here, we focus on the study of interaction between human microbiota and the development and progression of infectious diseases such as frequent emerging infectious diseases, C.difficile infection, HIV infection, and Hepatitis B related liver disease. Hepatitis B related liver disease is a very important infectious disease in China. Appropriate treatment can prevent the development of the major life-threatening complications of chronic liver disease: cirrhosis, acute-on-chronic liver failure, and liver cancer, which can lead to death. Thus, the recent researches on human microbiota had been made much progress. The research on human microbiota has become much more sophisticated and more comprehensive. We proposed “three T” proposal for Infectious diseases: Tool: Based on B/E value or 16S rRNA sequencing to detect gut microbiota dysbiosis should be a routine tool; Target, Keeping homeostasis of human microbiota should be a new medical target; Therapy, Modulation on gut microbiome should be an essential therapy. And I believe that our research focus on the host-microbe interaction and the cause-effect mechanism, which will provide a new therapeutic target and pave the way to understand the human microbiota secret.
日期：11月24日（周四）15:00-16:00
地点：清华大学医学科学楼B323
